Suchen
TG Therapeutics Inc
TGTXZur Watchlist hinzufügen
56.286USD
+0.566+1.02%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
8.62BMarktkapitalisierung
17.58KGV TTM
mehr Informationen über TG Therapeutics Inc Unternehmen
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc Informationen
BörsenkürzelTGTX
Name des UnternehmensTG Therapeutics Inc
IPO-datumDec 14, 1995
CEOWeiss (Michael S)
Anzahl der mitarbeiter338
WertpapierartOrdinary Share
GeschäftsjahresendeDec 14
Addresse3020 Carrington Mill Blvd., Suite 475
StadtMORRISVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl27560-5435
Telefon18775758489
Websitehttps://www.tgtherapeutics.com/
BörsenkürzelTGTX
IPO-datumDec 14, 1995
CEOWeiss (Michael S)
Führungskräfte von TG Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von TG Therapeutics Inc?
Die fünf größten Anteilseigner von TG Therapeutics Inc sind: Mr. Michael S. Weiss, J.D.
Wie viele Institutionen halten Anteile an TG Therapeutics Inc (TGTX)?
Mit Stand vom 2026Q1 halten 760 Institutionen Anteile an TG Therapeutics Inc, mit einem Gesamtmarktwert von etwa 122.50M, was 80.02% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 4398281.00 gestiegen.
Was ist die größte Einnahmequelle von TG Therapeutics Inc?
Am 2026Q1 erzielte das Geschäft mit Total product revenue, net für TG Therapeutics Inc den höchsten Umsatz in Höhe von 606.93M, was 98.48% des Gesamtumsatzes entspricht.
